Akebia Therapeutics, Inc. is a biopharmaceutical company that focuses on the development and commercialization of therapeutics for patients with kidney disease. The company's lead product candidate, vadadustat, is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that is in Phase III development for the treatment of anemia due to chronic kidney disease. Akebia's headquarters are located in Cambridge, Massachusetts, and the company operates in the United States and internationally. The company was founded in 2007.